Hematologic Cancer Research at Providence Cancer Center

The immune system has immense potential to destroy tumors while sparing normal tissue. Developing new immuno-oncology therapies for blood-related cancers is the primary focus of the Hematologic Malignancies Program at Providence Cancer Center. 

Hematologic cancers are diverse, and their treatment is complex. Providence Cancer Center’s QOPI-certified team offers an extraordinary level of expertise in treating leukemia, myeloma, myelodysplastic syndrome, Hodgkin and non-Hodgkin lymphoma and other hematologic malignancies. Under the leadership of John Godwin, M.D., our multidisciplinary team offers patient-focused care, expert second opinions for complex cases, and cutting-edge clinical and translational research trials of the most promising agents. Many of our trials are first-in-human studies of new immuno-oncology therapies. 

Currently, 16 studies are open to patients, including: 

A CAR T-cell immunotherapy treatment for patients with mantle cell lymphoma 
Title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) 

A study of an antibody-drug conjugate for myelodysplastic syndrome (MDS) 
Title: A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) 

View all open studies for patients with hematologic cancers ›
View all Providence Cancer Center studies in all cancer types ›